EUVIMEDEUVIMED entdecken
Crossref

Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct‐acting antiviral agents

Hideko Ohama iD, Atsushi Hiraoka iD, Toshifumi Tada iD, Kazuya Kariyama iD, Ei Itobayashi, Kunihiko Tsuji, Toru Ishikawa iD, Hidenori Toyoda iD, Takeshi Hatanaka iD, Satoru Kakizaki, Atsushi Naganuma, Fujimasa Tada und 6 weitere

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16553 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Hideko Ohama und 17 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan. Hauptthemen laut MEDLINE: Antiviral Agents, Carcinoma, Hepatocellular, Hepatitis C, Chronic, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Direct‐acting antivirals (DAAs) have been accessible in Japan since 2014. The aim of this study is to compare how the prognosis of patients with hepatitis C virus (HCV)‐associated hepatocellular carcinoma (HCV‐HCC) changed before and after DAA development.

Methods

A retrospective analysis of 1949 Japanese HCV‐HCC patients from January 2000 to January 2023 categorized them into pre‐DAA (before 2013, n = 1169) and post‐DAA (after 2014, n = 780) groups. Changes in clinical features and prognosis were assessed.

Results

Despite no significant differences in BCLC stage between groups, the post‐DAA group exhibited higher rates of sustained virological response (SVR) (45.6% vs. 9.8%), older age (73 vs 69 years), lower levels of AST (40 vs 56 IU/L), ALT (31 vs 46 IU/L), and AFP (11.7 vs 23.6 ng/mL), higher platelet count (13.5 vs 10.8 × 10 4 /μL), better prothrombin time (88.0% vs 81.9%), and better ALBI score (−2.54 vs −2.36) (all P < 0.001). The post‐DAA group also showed higher rates of curative treatments (74.1% vs 65.2%) and significantly improved recurrence‐free survival (median 2.8 vs 2.1 years). Adjusted for inverse probability weighting, overall survival was superior in the post‐DAA group (median 7.4 vs 5.6 years, P < 0.001). Subanalysis within the post‐DAA group revealed significantly shorter overall survival for patients without SVR (median 4.8 years vs NA vs NA) compared to pre‐SVR or post‐SVR patients (both P < 0.001). No significant difference in OS was observed between the pre‐SVR and post‐SVR groups ( P = 1.0).

Conclusion

The development of DAA therapy has dramatically improved the prognosis of HCV‐HCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCarcinoma, HepatocellularHepatitis C, ChronicLiver NeoplasmsSustained Virologic ResponseAgedFemaleHumansMaleMiddle AgedAge FactorsEast Asian PeopleHepacivirusJapanPrognosisRetrospective StudiesSurvival RateTreatment Outcome

Stichwörter der Autor:innen

direct‐acting antiviralshepatitis C virushepatocellular carcinoma

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Department of Gastroenterology, Takarazuka City Hospital, Hyogo, Japan.
  • Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Department of Hepatology, Okayama City Hospital, Okayama, Japan.
  • Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
  • Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.

ORCID-Profile: Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Kazuya Kariyama, Toru Ishikawa, Hidenori Toyoda, Takeshi Hatanaka, Kazuhiro Nouso, Kazunari Tanaka, Takashi Kumada

Zitieren

APA

Ohama, H., Hiraoka, A., Tada, T., Kariyama, K., Itobayashi, E., Tsuji, K., Ishikawa, T., Toyoda, H., Hatanaka, T., Kakizaki, S., Naganuma, A., Tada, F., Tanaka, H., Nakamura, S., Nouso, K., Tanaka, K., Kumada, T., & Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) (2024). Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct‐acting antiviral agents. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16553

Vancouver

Ohama H, Hiraoka A, Tada T, Kariyama K, Itobayashi E, Tsuji K, et al. Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct‐acting antiviral agents. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16553

BibTeX
@article{Ohama2024,
  author = {Ohama, Hideko and Hiraoka, Atsushi and Tada, Toshifumi and Kariyama, Kazuya and Itobayashi, Ei and Tsuji, Kunihiko and Ishikawa, Toru and Toyoda, Hidenori and Hatanaka, Takeshi and Kakizaki, Satoru and Naganuma, Atsushi and Tada, Fujimasa and Tanaka, Hironori and Nakamura, Shinichiro and Nouso, Kazuhiro and Tanaka, Kazunari and Kumada, Takashi and Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)},
  title = {Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct‐acting antiviral agents},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16553}
}
Kostenlos starten →